This public health crisis highlights the importance of robust health systems to respond to outbreaks like COVID-19 and to control other deadly diseases such as malaria. On World Malaria Day, April 25, we are calling on the global health community to uphold progress and commitments made in the fight to end malaria.
Follow us on social media at #MalariaFuture
…
Sofia* has breast cancer. Each month she travels from her home in Eastern Europe to a hospital in northern Italy to participate in a clinical trial. Traveling such distances for a clinical trial is uncommon, but Sofia was eager to participate in this particular trial for her condition.
But everything changed when the coronavirus (COVID-19) took hold on the continent. With transport links rapidly shutting down due to the pandemic, Sofia was no longer able to make the trip to Italy. With only two weeks’ worth of medication remaining and very little prospect of being able to obtain any …
Basel, April 20, 2020 — Novartis announced today that it has completed the acquisition of Amblyotech, a US-based …
Novartis is teaming up with R&D leaders throughout the industry as part of the National Institutes of Health (NIH) and the Foundation for NIH (FNIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership initiative. Collaboration and open innovation are essential elements of the fight against this global pandemic. Novartis is committed to doing our part as an active contributor to the global effort underway to combat COVID-19.
The National Institutes of Health and the Foundation for the NIH are bringing together more than a dozen …
We are grateful to all patient organizations who have provided feedback on our work and take the opportunity to thank them for the hard work they are doing to support patients around the world, particularly in these challenging times of the COVID-19 crisis.
The Corporate Reputation of Pharma 2019 global report is based on the findings of a survey conducted by PatientView from November 2019 to February 2020.
In this report Novartis ranked #4 in overall reputation with patient organizations and #2 in corporate brand awareness.
In our Commitment to Patients and …
We are grateful to all patient organizations who have provided feedback on our work and take the opportunity to thank them for the hard work they are doing to support patients around the world, particularly in these challenging times of the COVID-19 crisis.
The Corporate Reputation of Pharma 2019 global report is based on the findings of a survey conducted by PatientView from November 2019 to February 2020.
In this report Novartis ranked #4 in overall reputation with patient organizations and #2 in corporate brand awareness.
In our Commitment to Patients and …
As a physician-scientist who has spent much of my career working on drug and vaccine development, including during the H1N1 pandemic, I’ve been getting many questions about my take on the COVID-19 response. I wanted to answer a few of the most common questions in case they’re on your mind as well.
As I recently shared in an article on COVID-19, I believe we’re in the midst of by far the …
Basel, April 8, 2020 — Patient safety is at the heart of everything we do. Whenever adverse events are reported, we take them seriously and investigate them thoroughly.
As part of its safety surveillance program, Novartis has been actively evaluating post-marketing cases reported as severe vision loss, retinal artery occlusion and/or vasculitis with Beovu® (brolucizumab). We have been working closely with the reporting physicians and retina specialists to get their perspective and collect the relevant clinical and imaging data in a manner compliant with …
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
+263 (242) 741 308
+263 (242) 741 309
Mon-Fri: 8am – 5pm
